Jing L. Marantz, Executive Vice President and Chief Medical Officer of Intellia Therapeutics, Inc., filed a Form 4 on October 28, 2026, disclosing equity awards granted on October 26, 2026.

Key Highlights

  • RSU grant: Marantz acquired 199,822 restricted stock units representing a contingent right to receive one share of Intellia common stock per unit, at a price of $0.00, on October 26, 2026.
  • Stock option grant: Marantz also acquired a stock option (right to buy) covering 275,061 shares of common stock, with an exercise price of $11.26, granted on October 26, 2026.
  • Option expiration: The stock option expires on October 25, 2036, according to the filing.
  • Vesting schedule: The option vests with 33% on October 26, 2027, and the remaining 67% in 24 substantially equal monthly installments thereafter.
  • Resulting ownership: Following these transactions, Marantz directly holds 199,822 shares and 275,061 derivative securities, per the filing.
  • Filing price for option: The price of the derivative security is listed as $0 in the filing.

Equity Awards to Intellia's Chief Medical Officer on October 26, 2026

According to the Form 4 filed with the SEC on October 28, 2026, Jing L. Marantz, identified as EVP and Chief Medical Officer of Intellia Therapeutics, Inc. (NASDAQ:NTLA), received two equity awards on October 26, 2026. The first is a grant of 199,822 restricted stock units (RSUs), each representing a contingent right to receive one share of Intellia common stock. The RSUs were acquired at a price of $0.00, and Marantz directly holds 199,822 shares of common stock following this transaction.

The second award is a stock option granting the right to purchase 275,061 shares of common stock at an exercise price of $11.26 per share. The filing states the option was granted on October 26, 2026, and expires on October 25, 2036. Per the filing, 33% of the option vests on October 26, 2027, with the remaining 67% vesting "in 24 substantially equal monthly installments thereafter." The price of the derivative security is reported as $0. Following this grant, Marantz directly holds 275,061 derivative securities in the form of stock options.

The Form 4 was signed by James Basta as attorney-in-fact on October 28, 2026. The filing was made by one reporting person, and no indirect ownership was reported for either award.

What Was Disclosed

Intellia Therapeutics' Chief Medical Officer Jing L. Marantz disclosed receipt of 199,822 RSUs and a stock option for 275,061 shares at $11.26, both granted October 26, 2026, with the option expiring October 25, 2036.